Ruxolitinib improves hematocrit control and treatment response in polycythemia vera compared to best available therapy. Patients on ruxolitinib show better Myeloproliferative Neoplasms-Symptom ...

The lower number needed to treat suggests that ruxolitinib cream may be more effective for patients with atopic dermatitis (AD), according to a poster presented at AMCP 2023. Compared with other ...

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis ...

Ruxolitinib (Opzelura) cream can help repigment the skin in many body areas affected with vitiligo, researchers reported at the European Academy of Dermatology and Venereology (EADV) 2022 Annual ...

Jak1/2 inhibitor ruxolitinib is a promising agent for treating steroid-refractory GvHD after allogeneic hematopoietic stem cell transplantation (SCT) to produce quick and durable responses. However, ...

The evaluation committee considered evidence submitted by Novartis Pharmaceuticals, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

MILAN — Ruxolitinib (Jakafi, Incyte) led to substantial improvements in patients with polycythemia vera (PV), a chronic and incurable blood cancer, in the first pivotal phase 3 study of the agent. The ...

For patients with vitiligo, ruxolitinib cream results in greater repigmentation of lesions compared with vehicle control, according to a study published online Oct. 20 in the New England Journal of ...